Chinese women aged 65 years or older have significantly higher rates of high-risk human papillomavirus infection and cervical ...

Concurrent chemoradiotherapy (CCRT) is recently recommended as the primary and standard treatment modality for cervical cancer. The aim of this study is to investigate the protein biomarkers ...

Using cervical-carcinoma-derived cells as a model, the present study investigates the effects cell line and cell cycle phase have on sonoporation transfection efficiency under the same physical ...

Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic ...

Physiological parameters can be estimated from dynamic contrast enhanced magnetic resonance imaging (DCEMRI) data using pharmacokinetic models. This work evaluates the performance of various ...

DUCTAL CARCINOMA in situ is defined as a breast lesion in which neoplastic mammary epithelial cells are confined to the mammary ductal-lobular system without invasion into the surrounding stroma. DCIS ...

The estimated lifetime risk of being diagnosed with cervical cancer is 1 in 130 (1%) for females born in 1961 in the UK.[1] These figures have been calculated on the assumption that the possibility of ...

5. Costales AB, Milbourne AM, Rhodes HE, Munsell MF, Wallbillich JJ, Brown J, et al. Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. Gynecol ...

Human Papillomavirus E6/E7 mRNA Testing as a Predictive Marker for Cervical Carcinoma Agnes Kathrine Lie, MD, PhD; Gunnar Kristensen, MD, PhD Disclosures Expert Rev Mol Diagn. 2008;8 (4):405-415.